Blackford at RSNA 2021: It’s Time to Realize the Value of AI

World’s broadest AI imaging marketplace enables unbiased navigation of medical imaging AI to identify the best-suited applications, measure their potential, and realize the value that they can deliver

Blackford Analysis, the platform for medical imaging applications and AI, today unveiled its latest vision at RSNA 2021. The platform now provides a standardized, unbiased approach to the largest number of medical imaging AI algorithms on the market.

Through Blackford’s curated market of integrated AI applications, healthcare organizations can identify the applications best suited to their organization, measure their potential, roll them out, and realize the value that they can deliver. Serving more than 750 sites across the world, the platform currently provides access to 56 regulatory cleared clinical applications, with more joining every month.

Blackford will be showcasing several exciting new AI applications at RSNA that are now available on its platform, as well as highlighting key new partnerships with 3M Health Information Systems, Bialogics and EBIT, Esaote.

3M M*Modal Fluency for Imaging combines advanced speech recognition technology, computer-assisted physician documentation (CAPD) for real-time clinical insights, information-enabled workflow management and productivity-enhancing tools.

Bialogics identifies, extracts, and correlates data from diagnostic reports to provide analysis of AI/ML algorithms AI analysis to unlock clinical and operational insights hidden within discrete and narrative data elements.

Ebit, Esaote Group integrates within the Blackford RIS-CVIS PACS environment, allowing enhanced clinical solutions to physicians.

“When navigating the AI landscape, nothing is more important than access to a broad offering of applications from a platform provider who is free of clinical bias and has a history of success in delivery within the AI marketplace space,” said Ben Panter, CEO, Blackford. “We originated the AI marketplace concept and offer the broadest integrated suite of medical imaging in the market today. As the leading marketplace provider, we believe in integrity and the opportunity to navigate without risk and bias.”

Navigate the market

Blackford’s unbiased, open vendor approach provides access to the widest selection of regulatory cleared medical imaging AI applications and allows any application on the market to be quickly added – including those developed in-house.

“Our established frameworks allow healthcare organizations to determine the most accurate and valuable solutions with a fraction of the IT and clinical resources when compared to any other marketplaces or direct interactions with AI vendors,” said Panter.

Measure the potential

The platform allows providers to accelerate the evaluation process of any given AI algorithm by providing tools to dramatically compress the time and investment required to assess and quickly determine their appropriateness and applicability.

“We use evidence to help define our customers’ AI strategy and avoid time-consuming trial-and-error attempts, while reducing the internal and external costs of AI evaluation,” said Panter.

Realize the value

But the ultimate goal of Blackford’s dedicated platform is to help healthcare organizations realize and enhance the value of medical imaging AI applications over time – delivering economies of scale to magnify the benefits.

“We do this by quickly and easily deploying applications, innovating the workflow integrations, orchestration and tools required, and continually measuring application performance as the AI market develops,” said Panter. “We enable the clarity of an algorithm’s value and performance over time, providing greater confidence for the continuation of program funding and long-term application utilization.”

Also, at RSNA this year, on Wednesday, December 1st, at 11:30 a.m. CST Blackford CEO Ben Panter will deliver an Industry Presentation entitled What’s Holding AI Back? The presentation will address the key challenges that must be overcome to make AI a commercial success in medical imaging.

More here.

SourceBlackford
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.
The rehabilitation robotic glove is a training device that combines EMG electromyographic feedback and flexible robotics for patients with stroke or hand disabilities to train and repair dexterity.
Conformal Medical is actively enrolling patients in the CONFORM pivotal trial, evaluating the safety and efficacy of the CLAAS System compared to other commercially available LAAO devices. The prospective, multicenter, randomized controlled study will enroll approximately 1,600 patients.
“This should be welcome news for patient care teams because a greater prediction rate with fewer false alerts translates into more effective and efficient care,” said Corey Centen, founder, president, and chief technical officer at Bodyport. “What’s more, use of the Cardiac Scale and the Congestion Index is a seamless transition for clinicians and patients because it enhances, rather than replaces, the existing pathways built around weight monitoring. The lower alert rate should lead to workflow efficiencies because care teams—who are often feeling overly burdened by the large number of notifications and data flowing in—will spend less time responding to false alerts.”
The potential of BC 007 extends beyond treating a single disease, making it a so-called platform technology. By neutralizing fAABs, BC 007 could potentially act against many fAAB-associated diseases.

By using this website you agree to accept Medical Device News Magazine Privacy Policy